Considering the central role of HSP90 in regulating the activation and dimerization of receptor tyrosine kinases such as HER2, HER3, and EGFR 5, targeting HSP90 represents a promising clinical strategy for treating breast cancer. This evidence concerns the gene HSP90AA1 and breast carcinoma.